Smart Starting Material Selection for Better Cells and Better Therapies
SHARE NOW
WATCH ON DEMAND – ABOVE | MEET THE PANEL
How can we delve deeper into the characterization of cell and donor screening? While cell-based immunotherapies are showing great promise in cancer indications, some issues still need to be addressed, including the variability in clinical outcomes and lack of durable responses noted at times.
Traditional applications of starting material selection have been limited in their ability to comprehensively assess donor suitability for cell and gene therapies, and this can lead to less potent and more variable final cell therapy products, which can contribute to variable and less durable clinical responses.
Have you considered each cell donor’s immune cell profile? Looked beyond surface markers, perhaps? Or even assessed the metabolic and effector potential of starting material cells?
So how can developers holistically approach suitability, considering donor demographics, recruitability, metabolic fitness, and effector function potential?
Join us as a panel of experts discusses challenges in starting material selection/endpoint characterization, highlighting the power of data analytics and machine learning algorithms. The panel of industry leaders will also share insights into which key factors have been implemented in their experience, to ensure maximum process and product safety.
WHAT TO EXPECT
Part 1: The panel will discuss the importance of effective donor selections for cell therapy:
- How to identify optimal starting materials to complement your clinical delivery strategy
- Approaches for improving the potency of cell-based treatments
- Reducing the limitations caused by variabilities in patient outcomes
- Exploring end-to-end solutions for partners to use in-part or as a whole
Part 2: The speakers answer audience questions with an interactive Q&A
MEET THE PANEL
Chase Monckton, PhD
Senior Technical Lead, Manufacturing & Research Services
Excellos™ Inc.
Robert Tressler, PhD
Chief Scientific Officer
Excellos™ Inc.
James Bender, PhD
Consultant
James Bender Consulting
This webinar is brought to you in partnership with Excellos™